Where does all that VC money go?
With every check-cashing biotech press release comes a cheerful description of how the company in question is going to use its newfound cash to bend the arc of modern medicine toward health. But how closely are those promises kept?
STAT’s Kate Sheridan, in a regular series called Something Ventured, catches up with investment recipients to see how things are panning out a year after the wire transfer hits. In the latest incarnation, you’ll find a name change, a CEO vacancy, and, for the cancer-focused Akrevia Therapeutics, a need for more space.
“Right now we’re pretty much right on top of each other,” Akrevia president Tim Clackson said. “Which is great for culture — up to a point.”
Read more.
STAT’s Kate Sheridan, in a regular series called Something Ventured, catches up with investment recipients to see how things are panning out a year after the wire transfer hits. In the latest incarnation, you’ll find a name change, a CEO vacancy, and, for the cancer-focused Akrevia Therapeutics, a need for more space.
“Right now we’re pretty much right on top of each other,” Akrevia president Tim Clackson said. “Which is great for culture — up to a point.”
Read more.
No hay comentarios:
Publicar un comentario